Literature DB >> 9398167

Solution structure of the aminofluorene-intercalated conformer of the syn [AF]-C8-dG adduct opposite a--2 deletion site in the NarI hot spot sequence context.

B Mao1, A Gorin, Z Gu, B E Hingerty, S Broyde, D J Patel.   

Abstract

This paper addresses structural issues related to the capacity of aminofluorene [AF] for frameshift mutations of the -2 type on C8 covalent adduct formation at the G3 site in the d(C-G1-G2-C-G3-C-C) NarI hot spot sequence. This problem has been approached from a combined NMR and relaxation matrix analysis computational structural study of the [AF]dG adduct in the d(C-G-G-C-[AF]G-C-C).d(G-G-C-C-G) sequence context at the 12/10-mer adduct level (designated [AF]dG.del(-2) 12/10-mer). The proton spectra of this system are of exceptional quality and are consistent with the formation of an AF-intercalated conformer with the modified guanine in a syn alignment displaced along with the 5'-flanking cytosine residue into the major groove. The solution structure has been determined by initially incorporating intramolecular and intermolecular proton-proton distances defined by lower and upper bound deduced from NOESY spectra as restraints in molecular mechanics computations in torsion angle space and subsequently refined through restrainted molecular dynamics calculations based on a NOE distance and intensity refinement protocol. Strikingly, the [AF]dG.del(-2) 12/10-mer duplex adopts only one of two potential AF-intercalation alignments for the [AF]dG adduct opposite the -2 deletion site in the NarI sequence context with the extrusion of the dC-[AF]dG step favored completely over extrusion of the [AF]dG-dC step at the lesion site. This polarity establishes that the structural perturbation extends 5' rather than 3' to the [AF]dG lesion site in the adduct duplex. This structure of the [AF]dG adduct opposite a -2 deletion site shows distinct differences with conclusions reported on the alignment of the related acetylaminofluorene [AAF]dG adduct opposite a -2 deletion site in the identical NarI sequence context [Milhe, C., Fuchs, R. P. P., and Lefevre, J. F. (1996) Eur. J. Biochem. 235, 120-127]. In that study, qualitative NMR data without computational analysis were employed to conclude that the extrusion at the lesion site occurs at the [AAF]dG-dC step for the AAF-intercalated conformer of the adduct duplex. The structure of the [AF]dG adduct opposite a -2 deletion site determined in our group provides molecular insights into the architecture of extended slipped mutagenic intermediates involving aromatic amine intercalation and base-displaced syn modified guanines in AF and, by analogy, AAF-induced mutagenesis in the NarI hot spot sequence context.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9398167     DOI: 10.1021/bi972205z

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  12 in total

1.  The C8-2'-deoxyguanosine adduct of 2-amino-3-methylimidazo[1,2-d]naphthalene, a carbocyclic analogue of the potent mutagen 2-amino-3-methylimidazo[4,5-f]quinoline, is a block to replication in vitro.

Authors:  Plamen P Christov; Goutam Chowdhury; Craig A Garmendia; Feng Wang; James S Stover; C Eric Elmquist; Albena Kozekova; Karen C Angel; Robert J Turesky; Michael P Stone; F Peter Guengerich; Carmelo J Rizzo
Journal:  Chem Res Toxicol       Date:  2010-06-21       Impact factor: 3.739

2.  Translesion synthesis past the C8- and N2-deoxyguanosine adducts of the dietary mutagen 2-Amino-3-methylimidazo[4,5-f]quinoline in the NarI recognition sequence by prokaryotic DNA polymerases.

Authors:  James S Stover; Goutam Chowdhury; Hong Zang; F Peter Guengerich; Carmelo J Rizzo
Journal:  Chem Res Toxicol       Date:  2006-11       Impact factor: 3.739

3.  Chemical and electrochemical oxidation of C8-arylamine adducts of 2'-deoxyguanosine.

Authors:  James S Stover; Madalina Ciobanu; David E Cliffel; Carmelo J Rizzo
Journal:  J Am Chem Soc       Date:  2007-01-26       Impact factor: 15.419

4.  Conformational interconversion of the trans-4-hydroxynonenal-derived (6S,8R,11S) 1,N(2)-deoxyguanosine adduct when mismatched with deoxyadenosine in DNA.

Authors:  Hai Huang; Hao Wang; R Stephen Lloyd; Carmelo J Rizzo; Michael P Stone
Journal:  Chem Res Toxicol       Date:  2009-01       Impact factor: 3.739

5.  Base-displaced intercalated structure of the food mutagen 2-amino-3-methylimidazo[4,5-f]quinoline in the recognition sequence of the NarI restriction enzyme, a hotspot for -2 bp deletions.

Authors:  Feng Wang; Nicholas E DeMuro; C Eric Elmquist; James S Stover; Carmelo J Rizzo; Michael P Stone
Journal:  J Am Chem Soc       Date:  2006-08-09       Impact factor: 15.419

6.  Conformational Insights into the Mechanism of Acetylaminofluorene-dG-Induced Frameshift Mutations in the NarI Mutational Hotspot.

Authors:  Lifang Xu; Bongsup P Cho
Journal:  Chem Res Toxicol       Date:  2016-01-15       Impact factor: 3.739

7.  Structure and thermodynamic insights on acetylaminofluorene-modified deletion DNA duplexes as models for frameshift mutagenesis.

Authors:  Anusha Sandineni; Bin Lin; Alexander D MacKerell; Bongsup P Cho
Journal:  Chem Res Toxicol       Date:  2013-06-04       Impact factor: 3.739

8.  Synthesis of oligonucleotides containing the N2-deoxyguanosine adduct of the dietary carcinogen 2-amino-3-methylimidazo[4,5-f]quinoline.

Authors:  James S Stover; Carmelo J Rizzo
Journal:  Chem Res Toxicol       Date:  2007-10-04       Impact factor: 3.739

9.  Probing the sequence effects on NarI-induced -2 frameshift mutagenesis by dynamic 19F NMR, UV, and CD spectroscopy.

Authors:  Nidhi Jain; Yuyuan Li; Li Zhang; Srinivasa R Meneni; Bongsup P Cho
Journal:  Biochemistry       Date:  2007-10-26       Impact factor: 3.162

10.  DNA sequence modulates the conformation of the food mutagen 2-amino-3-methylimidazo[4,5-f]quinoline in the recognition sequence of the NarI restriction enzyme.

Authors:  Feng Wang; C Eric Elmquist; James S Stover; Carmelo J Rizzo; Michael P Stone
Journal:  Biochemistry       Date:  2007-06-30       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.